Founded in 2003, NanoString Technologies is a privately held provider of life science tools for translational research and developer of molecular diagnostic products. The company's nCounter® Analysis System, has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 180 peer-reviewed publications, has also now been optimized as a diagnostic platform. The system offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. The company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The nCounter®-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay, which has been launched in the EU and Israel, is the first in vitro diagnostic kit to be marketed through the company's recently formed diagnostics business.
The NanoString system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including formalin-fixed, paraffin-embedded (FFPE) tissues. – less